BACKGROUND/AIMS: Depression is common in patients with end-stage renal disease (ESRD) on hemodialysis (HD). Although, depression is associated with mortality, the effect of depression on in-hospital outcomes has not been studied as yet. METHODS: We analyzed the National Inpatient Sample for trends and outcomes of hospitalizations with depression in patients with ESRD. RESULTS: The proportion of ESRD hospitalizations with depression doubled from 2005 to 2013 (5.01-11.78%). Hospitalized patients on HD with depression were younger (60.47 vs. 62.70 years, p < 0.0001), female (56.93 vs. 47.81%, p < 0.0001), white (44.92 vs. 34.01%, p < 0.0001), and had higher proportion of comorbidities. However, there was a statistically significant lower risk of mortality in HD patients within the top 5 reasons for admissions. CONCLUSION: There were significant differences in demographics and comorbidities for hospitalized HD patients with depression. Depression was associated with an increased rate of adverse effects in discharged patients, and decreased in-hospital mortality.
BACKGROUND/AIMS: Depression is common in patients with end-stage renal disease (ESRD) on hemodialysis (HD). Although, depression is associated with mortality, the effect of depression on in-hospital outcomes has not been studied as yet. METHODS: We analyzed the National Inpatient Sample for trends and outcomes of hospitalizations with depression in patients with ESRD. RESULTS: The proportion of ESRD hospitalizations with depression doubled from 2005 to 2013 (5.01-11.78%). Hospitalized patients on HD with depression were younger (60.47 vs. 62.70 years, p < 0.0001), female (56.93 vs. 47.81%, p < 0.0001), white (44.92 vs. 34.01%, p < 0.0001), and had higher proportion of comorbidities. However, there was a statistically significant lower risk of mortality in HDpatients within the top 5 reasons for admissions. CONCLUSION: There were significant differences in demographics and comorbidities for hospitalized HDpatients with depression. Depression was associated with an increased rate of adverse effects in discharged patients, and decreased in-hospital mortality.
Authors: Valeria Saglimbene; Suetonia Palmer; Marco Scardapane; Jonathan C Craig; Marinella Ruospo; Patrizia Natale; Letizia Gargano; Miguel Leal; Anna Bednarek-Skublewska; Jan Dulawa; Tevfik Ecder; Paul Stroumza; Angelo Marco Murgo; Staffan Schön; Charlotta Wollheim; Jörgen Hegbrant; Giovanni F M Strippoli Journal: Nephrol Dial Transplant Date: 2017-02-01 Impact factor: 5.992
Authors: Kenneth E Freedland; Michael W Rich; Judith A Skala; Robert M Carney; Victor G Dávila-Román; Allan S Jaffe Journal: Psychosom Med Date: 2003 Jan-Feb Impact factor: 4.312
Authors: Joseph E Tanenbaum; Daniel Lubelski; Benjamin P Rosenbaum; Nicolas R Thompson; Edward C Benzel; Thomas E Mroz Journal: Spine J Date: 2016-01-11 Impact factor: 4.166
Authors: Scott D Cohen; Lorenzo Norris; Kimberly Acquaviva; Rolf A Peterson; Paul L Kimmel Journal: Clin J Am Soc Nephrol Date: 2007-10-17 Impact factor: 8.237
Authors: Yumeng Wen; Changchuan Jiang; Holly M Koncicki; Carol R Horowitz; Richard S Cooper; Aparna Saha; Steven G Coca; Girish N Nadkarni; Lili Chan Journal: J Am Soc Nephrol Date: 2019-08-06 Impact factor: 10.121
Authors: Robin Lengton; Robbert W Schouten; Els Nadort; Elisabeth Fc van Rossum; Friedo W Dekker; Carl Eh Siegert; Ellen K Hoogeveen Journal: Clin Med Insights Endocrinol Diabetes Date: 2022-08-29